LINDEN ADVISORS LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 64 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
LINDEN ADVISORS LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$53,329,425
+11.5%
62,930,000
+9.6%
0.55%
+9.0%
Q2 2023$47,848,953
+410.3%
57,430,000
+420.2%
0.50%
+407.1%
Q1 2023$9,377,053
+284.8%
11,040,000
+341.6%
0.10%
+280.8%
Q4 2022$2,437,0002,500,0000.03%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 71,432$63,617,0004.32%
Western Asset Management Company, LLC 15,600,000$13,690,0004.04%
CAMDEN ASSET MANAGEMENT L P /CA 70,849,000$61,727,0001.84%
ZAZOVE ASSOCIATES LLC 16,992,000$14,985,0001.32%
Penn Mutual Asset Management, LLC 1,305,000$1,137,0001.32%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 64,750,000$56,413,0000.72%
CQS (US), LLC 10,000,000$8,777,0000.61%
ADVENT CAPITAL MANAGEMENT /DE/ 28,859,000$25,319,0000.40%
Context Capital Management, LLC 4,122$3,632,0000.24%
Hudson Bay Capital Management LP 19,500,000$17,152,0000.23%
View complete list of HALOZYME THERAPEUTICS INC shareholders